Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator

Cell

Volumn 62, Issue 3, 1990, Pages 447-456

  Heckel, Janice L ^a   Sandgren, Eric P ^b   Degen, Jay L ^a   Palmiter, Richard D ^c   Brinster, Ralph L ^b  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; HEREDITY; MOUSE; NEWBORN; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL;

ANIMAL; BASE SEQUENCE; BLOTTING, NORTHERN; FIBRINOGEN; GASTROINTESTINAL HEMORRHAGE; GENE EXPRESSION; GROWTH HORMONE; HUMAN; LIVER; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE PROBES; PHENOTYPE; PLASMINOGEN ACTIVATORS; PLATELET COUNT; PROTEIN PRECURSORS; RESTRICTION MAPPING; RNA; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; URINARY PLASMINOGEN ACTIVATOR;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0025144417     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/0092-8674(90)90010-C     Document Type: Article

References (41)

1. Thrombocytosis in infants and children
2. Hemostasis associated with abnormalities of fibrinolysis
3. Abnormal plasminogen
4. Congenital deficiency of α2-plasmin inhibitor associated with severe hemorrhagic tendency
5. Fibrinolytic status in a patient with congenital deficiency of α-2-plasmin inhibitor
6. Inherited fibrinolytic disorder due to an enhanced plasminogen activator level
7. Hemophilia in the first year of life
8. Transgenic mice express the human phenylethanolamine N-methyltransferase gene in adrenal medulla and retina
9. Plasminogen activator gene expression is induced by the src oncogene product and tumor promoters
10. A new life-long hemorrhagic disorder due to excess plasminogen activator
11. Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs
12. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease
13. Fibrinolysis and the control of hemostasis
14. Molecular cloning of cDNA for the α, β, and γ chains of rat fibrinogen
15. Plasminogen activators, tissue degradation, and cancer
16. Fibrinolysis at rest and after exercise in hepatic cirrhosis
17. A practical approach for quantitating specific mRNAs by solution hybridization
18. Abdominal trauma
19. A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity
20. Clinical disorders of fibrinolysis: a critical review
21. The murine urokinase-type plasminogen activator gene
22. Congenital heterozygous plasminogen deficiency associated with a severe thrombotic tendency
23. Studies of the procoagulant and fibronolytic activity of promyelocytes in acute promyelocytic leukemia
24. Fibrinolysis in patients with acute promyelocytic leukemia and disseminated intravascular coagulation during heparin therapy
25. Abnormal plasminogen, a case of recurrent thrombosis
26. Alpha-2-antiplasmin Enschede: a dysfunctional alpha-2-antiplasmin molecule, associated with an autosomal recessive hemorrhagic disorder
27. Severe hemorrhagic tendency in heterozygous α2-antiplasmin deficiency
28. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
29. Recurring thromboembolic disease and pulmonary hypertension associated with severe hypoplasminogenemia
30. Thrombolytic therapy: current status
31. A bleeding disorder due to deficiency of α-2-antiplasmin
32. Specific expression of an elastase-human growth hormone fusion gene in pancreatic acinar cells of transgenic mice
33. Blood coagulation and its disorders in the newborn
34. Manifestation and management of hypofibrinogenemia and fibrinolysis in patients with carcinoma of the prostate
35. An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice
36. Thrombolysis in myocardial infarction (TIMI) trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
37. Cell-associated plasminogen activation: regulation and physiological functions
38. Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis: case report and literature review
39. The human growth hormone gene family: nucleotide sequences show recent divergence and predict a new polypeptide hormone
40. Fibrinolysis in metastatic cancer of the prostate
41. Primary fibrinolysis in acute monocytic leukemia